“…In comparative studies, in light of similar rates of transplant-related (i.e., artery thrombosis) and unrelated (i.e., bleeding) complications (15,24,30,32,35,37), MP allowed for prolonged total graft preservation time (15,35), a 10%-50% reduced risk for EAD (7,17,24,30,36,37,41,47), 7%-15% less IRI (7,17,28,32,39,42), 7-50% fewer ischemic biliary complications (IBC) (7,15,17,24,30,31,36,37,47), comparable (22,24) or improved 1-year graft (30,47) and patient survival (30,35), and up to a 50% lower discard rate (31,35,43). Hospital stay was not longer for MP patients (15,24,30), and technical failures were anecdotal (36). Costs of MP have limitedly been investigated in two studies only (13,21).…”